Jingfeng Li | Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Jingfeng Li | Genetics and Molecular Biology | Best Researcher Award

School of Pharmacy, Yantai University | China

Dr. Jingfeng Li is a distinguished molecular biologist and biotechnology expert with extensive experience in cancer research and gene therapy innovation. He currently serves as a Professor at the School of Pharmacy, Yantai University, where he leads pioneering research on the molecular mechanisms underlying the tumor-suppressive effects of oncolytic HSV1 viruses across various solid tumors. Concurrently, as Chief Science Officer, Chief Scientist, and Deputy General Manager at Beijing WellGene Company Ltd., Dr. Li oversees the strategic development and implementation of advanced gene therapy pipelines, guiding the company’s research, innovation, and product development in alignment with global biomedical trends. His career reflects a deep commitment to translational research, having previously held academic positions at The Ohio State University, where his team investigated the molecular pathways driving HPV-associated head, neck, and cervical cancers, and conducted significant studies on transposon epigenetics and hereditary disease gene cloning. Earlier in his career, at the National Cancer Institute (NIH), he focused on DNA methylation and retrotransposon polymorphisms, contributing to foundational insights in tumor biology. Dr. Li’s entrepreneurial endeavors include founding Singlebase LLC in the United States, where he developed genetic testing products for targeted lung cancer therapy, including fusion detection and resistance mutation assays. A Ph.D. graduate from the Karolinska Institute in Cell and Tumor Biology, Dr. Li has been recognized for his leadership and innovation, notably as part of Beijing’s Overseas Talent Gathering Project and as a Yicheng Outstanding Talent. His work has been presented at major international conferences, including the International Papillomavirus Conference and the CGCS Summit on Cell and Gene Therapy, reflecting his global reputation in advancing the frontiers of molecular oncology and gene therapy.

Profile: Orcid

Featured Publications

Lv, J., Zhu, W., Xie, X., Tian, C., Zhu, C., Hu, Z., Li, Y., Shao, M., Liu, W., Ma, D., Wang, S., Li, X., & Li, J. (2026). Engineered oncolytic herpes simplex virus expressing interleukin 12 suppresses tumorigenicity of hepatocellular carcinoma. Biochimica et Biophysica Acta (BBA) – Molecular Basis of Disease, 1872(1), 168033.

Hu, Z., Liu, W., Liu, J., Zhou, H., Sun, C., Tian, C., Guo, X., Zhu, C., Shao, M., Wang, S., Zhu, W., Li, X., & Li, J. (2024). The anti-tumor efficacy of a recombinant oncolytic herpes simplex virus mediated CRISPR/Cas9 delivery targeting in HPV16-positive cervical cancer. Manuscript submitted for publication.

Zhu, W., Shao, M., Tian, C., Yang, J., Zhou, H., Liu, J., Sun, C., Liu, M., Wang, J., Zhu, C., Wei, L., Li, S., Li, X.#, & Li, J.# (2024). Synergistic induction of systemic antitumor immunity in bilateral tumor models through combined treatment with oncolytic virus VT1092M and anti-PD-L1 antibody.

Tian, C., Liu, J., Zhou, H., Li, J., Sun, C., Zhu, W., Yin, Y., & Li, X. (2021). Enhanced anti-tumor response elicited by a novel oncolytic HSV-1 engineered with an anti-PD-1 antibody. Cancer Letters, 518, 49–58.

Zhu, W., Lv, J., Xie, X., Tian, C., Liu, J., Zhou, H., Sun, C., Li, J., Hu, Z., & Li, X. (2021). The oncolytic virus VT09X optimizes immune checkpoint therapy in low immunogenic melanoma. Immunology Letters, 241, 15–22.

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Published on by Citation Awards

Anna Lankoff | Genetics and Molecular Biology | Best Researcher Award

Prof Anna Lankoff, Institute of Nuclear Chemistry and Technology, Centre for Radiobiology and Biological Dosimetry, Poland

Prof. Anna Lankoff is a distinguished scientist and educator renowned for her contributions to genotoxicology, nanotoxicology, and radiobiology. 👩‍🔬🧪 With over three decades of experience, she has made groundbreaking advancements in the study of ionizing radiation-induced DNA damage, nanoparticle-based radioconjugates for cancer therapy, and cellular responses to nanomaterials. 🌐🔬 Currently, she holds full professorships at both the Institute of Nuclear Chemistry and Technology in Warsaw and Jan Kochanowski University in Kielce, where she leads the Cytogenetics and Genotoxicology Laboratories. 💡📘 Her collaborative work spans across institutions in Germany, Finland, Belgium, and the USA. She is a respected academic leader, actively participating in global expert committees including WHO-IARC and the European Radiation Research Council. 🌍📚 With 85 peer-reviewed papers, 3797 citations, and an h-index of 30, Prof. Lankoff exemplifies excellence in research and education, making her an ideal candidate for the Best Researcher Award. 🏆🔝

Publication Profile

Orcid

Education 

Prof. Anna Lankoff began her academic journey with an MSc in Biology (1986–1991) from Jan Kochanowski University, Kielce, Poland. 🎓🔬 She earned her PhD in Toxicology in 1999 from Maria Sklodowska-Curie University in Lublin, Poland. 💊📘 Her research prowess led her to complete a prestigious postdoctoral fellowship in 2003 at Wright State University in Dayton, Ohio, USA, in the Department of Biological Sciences. 🌍🧬 In 2007, she achieved her DSc (habilitation) in Biological Sciences from the Institute of Biochemistry and Biophysics of the Polish Academy of Sciences. 🧫📖 By 2014, she was awarded the title of Full Professor in Biological Sciences, marking a significant milestone in her academic career. 🌟 Her extensive academic preparation laid the foundation for a prolific scientific and educational path in radiobiology, cytogenetics, and nanotoxicology. 🧠💼

Experience 

Prof. Lankoff has an extensive academic and research career. Since 2014, she has been a Full Professor at both the Institute of Nuclear Chemistry and Technology, Warsaw, and Jan Kochanowski University, Kielce. 🧪🇵🇱 She leads laboratories in cytogenetics and genotoxicology. From 2009–2014, she served as Associate Professor at these institutions, and previously, as a lecturer and assistant since 1991. 📘👩‍🏫 Her international experience includes research stints at University of Duisburg-Essen (Germany), Wright State University (USA), VITO (Belgium), and Åbo Akademi University (Finland). 🌐🔍 She has mentored numerous students and professionals in molecular biology, immunology, and nanotoxicology. Her professional journey reflects dedication to excellence in both teaching and cutting-edge scientific research. 💡🧬

Awards and Honors 

Prof. Anna Lankoff’s contributions have been recognized internationally. 🌟 She was a working group member for the WHO-IARC (2006) and an expert for the EU’s “Epigenetic effects” radiation protection group (2017). 🌍🔬 She represented Poland on the ISO Radiology Standards Committee (2010–2015) and serves on the Scientific Council of the Institute of Nuclear Chemistry and Technology and the Polish Society for Radiation Research. 🇵🇱📘 She is also a member of the European Radiation Research Council since 2022. 🧪💡 Her work has earned her recognition for developing standards in biological dosimetry and contributions to nanotoxicology and radiation biology. 📜🔝 With a prolific academic record of 85 JCR-listed publications and over 3,700 citations, she holds an h-index of 30. 📚 Her impactful global collaborations, editorial work, and advisory roles highlight her as a true leader in radiobiological research and innovation. 🧬🏆

Research Focus 

Prof. Lankoff’s research integrates nanotechnology, radiobiology, and molecular biology. 🧬 Her focus areas include the genotoxicity and cytotoxicity of nanomaterials, development of nanoparticle-based radioconjugates for targeted cancer diagnosis and therapy, and the mechanisms of DNA damage and repair induced by ionizing radiation. 💥🧪 She investigates cellular responses such as cell cycle arrest, apoptosis, and pyroptosis in reaction to nanomaterial exposure and radiation treatment. 🧫 Her recent work explores nanotheranostics, blackcurrant-derived antioxidants, and radiosensitization strategies using natural compounds. 🌿💉 She also delves into biodistribution, pharmacokinetics of engineered nanostructures, and radiobiological safety, bridging basic science with translational medicine. 🌐🧠 Prof. Lankoff’s innovative research contributes to the development of safer nanomaterials and more effective cancer therapies, reinforcing her status as a pioneering researcher in modern molecular and radiation biology. 🧪🔬📈

Publication Top Notes

  1. 📘 Advances in Nanotheranostic Systems for Concurrent Cancer Imaging and Therapy: An Overview of the Last 5 Years (2024)

  2. 🧪 Nanoparticle-Based Radioconjugates for Targeted Imaging and Therapy of Prostate Cancer (2023)

  3. ☢️ Hypothermia Modulates NBS1, γH2AX and 53BP1 Foci in U2OS Cells Post Gamma Radiation (2022)

  4. 🍇 Blackcurrant Pomace Protects Rats from Testicular Oxidative Stress from Biodiesel Exhaust (2022)

  5. 🔬 Surface Modification of Gold Nanoparticles Triggers Pyroptosis-Inducing Cytokine Release (2022)

  6. 💉 Targeted NaA Nanozeolites for Prostate Cancer Therapy: Toxicity and Pharmacokinetics (2021)

  7. 🧬 Cisplatin Lowers Radiotherapy-Induced Micronuclei in Lymphocytes of Gynaecological Cancer Patients (2021)

  8. 📈 Coralyne Radiosensitizes A549 Cells by CDKN1A Upregulation Affecting G2/M Cell Cycle Arrest (2021)